GT Medical Technologies Announces New Center of Excellence for GammaTile® Treatment Program
GT Medical Technologies, known for its commitment to advancing care for patients facing brain tumors, recently designated Goodman Campbell Brain and Spine at Ascension St. Vincent as a new GammaTile® Center of Excellence. This recognition highlights the institution's exemplary leadership in patient education and clinical skill pertaining to the innovative GammaTile procedure.
The GammaTile treatment represents a significant advancement in brain tumor management. By delivering targeted radiation directly to the tumor site at the time of surgical removal, GammaTile enables oncologists to address cancer cells when they are at their most vulnerable, thereby reducing the chances of regrowth. Conventional radiation treatments often entail a waiting period post-surgery, which can allow cancer cells to proliferate, emphasizing the importance of this immediate intervention.
Recently honored physicians include Dr. Charles G. Kulwin, Dr. Troy D. Payner, and Dr. Kushal J. Shah, all neurosurgeons at Goodman Campbell Brain and Spine. Dr. Kulwin expressed pride in their innovative treatment options, stating, "With GammaTile, we can deliver radiation directly to the tumor site at the time of surgery without any delay. This allows us to provide a more effective treatment for our patients."
The GammaTile is a bioabsorbable collagen implant embedded with radiation seeds, FDA-cleared for operable brain tumors. Its design is specifically intended for insertion at the surgical cavity when the tumor is excised, resulting in localized treatment. This approach significantly minimizes harmful exposure to surrounding healthy brain tissue, aligning with GT Medical Technologies' mission to enhance the quality of life for those affected by brain tumors.
Since its official launch in the U.S. in March 2020, the GammaTile treatment has garnered adoption by over 100 leading medical centers. This growing acceptance underscores its pivotal role in both academic and community healthcare settings. GT Medical Technologies remains committed to driving innovation in the realm of brain tumor treatment, continuously seeking ways to improve patient outcomes.
In summary, the new designation of Goodman Campbell Brain and Spine as a GammaTile Center of Excellence not only reinforces their capabilities in providing advanced care for brain tumor patients but also emphasizes the company's broader dedication to pioneering treatments. As the need for effective cancer management increases, initiatives like these will hopefully bring innovative solutions to the forefront, offering hope to patients and families navigating challenging diagnoses.
For more detailed information about the GammaTile treatment, visit GammaTile's official site or follow their social media channels on Facebook, Instagram, LinkedIn, and X to stay updated on advancements in brain tumor therapy.
The GammaTile treatment represents a significant advancement in brain tumor management. By delivering targeted radiation directly to the tumor site at the time of surgical removal, GammaTile enables oncologists to address cancer cells when they are at their most vulnerable, thereby reducing the chances of regrowth. Conventional radiation treatments often entail a waiting period post-surgery, which can allow cancer cells to proliferate, emphasizing the importance of this immediate intervention.
Recently honored physicians include Dr. Charles G. Kulwin, Dr. Troy D. Payner, and Dr. Kushal J. Shah, all neurosurgeons at Goodman Campbell Brain and Spine. Dr. Kulwin expressed pride in their innovative treatment options, stating, "With GammaTile, we can deliver radiation directly to the tumor site at the time of surgery without any delay. This allows us to provide a more effective treatment for our patients."
The GammaTile is a bioabsorbable collagen implant embedded with radiation seeds, FDA-cleared for operable brain tumors. Its design is specifically intended for insertion at the surgical cavity when the tumor is excised, resulting in localized treatment. This approach significantly minimizes harmful exposure to surrounding healthy brain tissue, aligning with GT Medical Technologies' mission to enhance the quality of life for those affected by brain tumors.
Since its official launch in the U.S. in March 2020, the GammaTile treatment has garnered adoption by over 100 leading medical centers. This growing acceptance underscores its pivotal role in both academic and community healthcare settings. GT Medical Technologies remains committed to driving innovation in the realm of brain tumor treatment, continuously seeking ways to improve patient outcomes.
In summary, the new designation of Goodman Campbell Brain and Spine as a GammaTile Center of Excellence not only reinforces their capabilities in providing advanced care for brain tumor patients but also emphasizes the company's broader dedication to pioneering treatments. As the need for effective cancer management increases, initiatives like these will hopefully bring innovative solutions to the forefront, offering hope to patients and families navigating challenging diagnoses.
For more detailed information about the GammaTile treatment, visit GammaTile's official site or follow their social media channels on Facebook, Instagram, LinkedIn, and X to stay updated on advancements in brain tumor therapy.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.